WEBULL
News
XRTX
0.5581
-4.01%
-0.0233
Weekly Report: what happened at XRTX last week (1027-1031)?
Weekly Report · 6d ago
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Benzinga · 6d ago
XORTX Therapeutics Completes $1.1 Million Direct Offering
TipRanks · 10/31 20:56
XORTX Therapeutics Secures $1.1 Million in Direct Offering
TipRanks · 10/29 11:44
XORTX Therapeutics Raises $1.1 Million in Registered Direct Offering
Reuters · 10/29 11:01
Weekly Report: what happened at XRTX last week (1020-1024)?
Weekly Report · 10/27 10:34
XORTX Secures $1.1 Million in Direct Offering
TipRanks · 10/23 10:29
XORTX Therapeutics Announces US$1.1 Million Registered Direct Offering
Reuters · 10/23 10:04
XORTX Receives Nasdaq Notification for Bid Price Deficiency
TipRanks · 10/21 13:49
Xortx Therapeutics prices 1.75M shares at 63c in registered direct offering
TipRanks · 10/21 12:20
XORTX Therapeutics Announces US$1.1 Million Registered Direct Offering
Reuters · 10/21 12:09
XORTX ANNOUNCES PRICING OF US$1.1 MILLION REGISTERED DIRECT OFFERING
Reuters · 10/21 12:00
XORTX Receives Nasdaq Extension for Compliance
TipRanks · 10/21 10:29
XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00 bid price compliance
Seeking Alpha · 10/21 05:44
XORTX ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY
Reuters · 10/20 22:45
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
Barchart · 10/20 19:34
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/20 18:39
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/20 12:08
Weekly Report: what happened at XRTX last week (1013-1017)?
Weekly Report · 10/20 10:30
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/20 09:10
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.